Technology Listings


CXCR4 Modulator for the Treatment of Inflammation

Application

CXCR4 modulator that does not target prostaglandin pathway (does not inhibit COX pathway) for treatment of inflammation.

Key Benefits
  • New class of anti-inflammatory drugs targeting CXCR4 instead of COX pathway.
  • May serve as safe anti-inflammatory drugs.
Market Summary

CXC chemokine receptor 4 (CXCR4) and stromal cell-derived factor 1 (SDF-1) are a chemokine receptor and chemokine pair that play a critical role in cancer metastasis and inflammation. The COX pathway has long been used as the major target for anti-inflammatory drugs. Both traditional non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors exhibit their anti-inflammatory activity by inhibiting COX-2. The prolonged use of traditional anti-inflammatory drugs is associated with potential serious side effects such as kidney failure, ulcers and prolonged bleeding after an injury or surgery. Two NSAIDs were withdrawn from the market due to an increased risk of cardiovascular complications. Accumulating evidence suggests the involvement of CXCR4/SDF-1 interaction in various inflammatory diseases, including rheumatoid arthritis, autoimmune diseases, ischemic injuries, inflammatory bowel disease, and pneumonia.

Technical Summary

CXCR4 inhibitors are promising agents for the treatment of inflammation. A series of novel tertiary amine derivatives uniquely modulating CXCR4 were designed, synthesized, and evaluated. The central benzene ring linker and side chains were modified and optimized to study the structure–activity relationships. The compounds have been selected via in vitro testing to determine their CXCR4 modulating activities and potency. These compounds have the potential for complementary therapeutic strategy in inflammatory diseases, viral infections, and cancer metastasis.

Development Stage

Selected compounds were tested in animal models of inflammation.

Publications
Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
PCT PCT PCT/US2016/042021   7/13/2016   1/16/2018
Tech ID: 15100
Published: 4/10/2017
Category
Therapeutics

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Hyunsuk Shim
Renren Bai
Suazette Mooring

Keywords
Immunology/Inflammation
Small Molecule
Oncology
Microbiology/Infectious Diseases